Asset Publisher

null Felipe García´s group

Description

Clinical trials with therapeutic and preventive vaccine.

Long-term non progressors and elite controllers.

Our research group have been working in this field for the last 17 years focused in two topics of HIV research:

  1. Development and clinical trials of therapeutic and preventive vaccines
  2. Immunopathogenesis of HIV infection

These 2 topics are narrowly related and we have projects in these 2 fields.

Development and clinical trials of therapeutic and preventive vaccines
Our group has been involved in pivotal studies from more than 20 years including therapeutic vaccines based using dendritic cells as adjuvant, peptides and GMO (genetically modified organism) as ALVAC and MVA. In addition, we have performed the first in Spain phase I clinical trial of a preventive vaccine based on a candidate developed in the AIDS Research Network (RIS). We participate in national and international networks for the development of an HIV vaccine as EUROPRISE, RIS, Bill Gatell Foundation, HIVACAT, IHIVARNA, EHVA, EAVI, HIVACAR…Our next future goals are to develop a functional cure of HIV infection using therapeutic vaccines and to continue the development of HIV preventive candidates from HIVACAT or other collaborations.

Immunopathogenesis of HIV infection
This topic is related to the vaccine line, since it is important to understand better the imunopathogenesis of HIV infection to develop a successful preventive or therapeutic vaccine. The understanding of the correlates of protection and control of HIV infection are of paramount importance to develop a vaccine. We have been working for years in patients with extreme phenotypes as long-term non progressors, elite controllers and also in highly exposed non infected individuals. In addition, we have developed clinical trials to test strategies for a better understanding of HIV infection, as using immunomodulators, antifibrotic agents, postexposure prophylaxis,…

Related Assets

Members

Felipe García
M. Florencia Etcheverry
Emma Fernández
Jose M. Gatell
Lorna Leal
M. Carmen Ligero
Constanza Lucero
Marga Robau
Berta Torres

Related Assets

Related Assets

Publications

  • Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization. 
    Alberto C. Guardo, Carmen Elena Gómez2 *, Vicens Díaz-Brito3 , Judit Pich3 , Joan Albert Arnaiz3 , Beatriz Perdiguero2 Juan García-Arriaza2 , José Luis Jimenez4 , María Angeles Muñoz-Fernández4 , José M Gatell3 , Mariano Esteban2 , Juan Carlos López Bernaldo de Quirós4 , Felipe García3& , Montserrat Plana1& for the RISVAC02boost study.  Plos One in press 
  • Early diagnosis of HIV infection and of asymptomatic sexually transmitted infections among men who have sex with men 
    Josep Coll1,2 *, Sebastián Videla2,3 *, Agathe Leon4, Arelly Ornelas2, Felipe García4, Emma Fernández4, Lorna Leal4, José Luis Blanco4, Isabel Bravo2, Anna Chamorro2, Antonio Carrillo6, Jorge Saz6, Ferran Pujol6, Michael Meulbroek6, Hector Taboada6, Eduardo Ditzel6, Guillem Sirera2, Marta Piñol2, Francesc García-Cuyas2, Boris Revollo2, Victoria González7, Jordi Casabona7, Laia Ferrer7, Josep Maria Gatell4, Christian Brander1, Bonaventura Clotet.  Clin Microbiol Infect. 2017 Aug 23. pii: S1198-743X(17)30458-5. doi: 10.1016/j.cmi.2017.08.012. [Epub ahead of print] 
  • Monocytes phenotype and cytokine production in HIV-1 infected patients receiving a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B): relationship to CD300 molecules expression. 
    Joana Vitallé1, Olatz Zenarruzabeitia1, Iñigo Terrén1, Montserrat Plana2, Alberto Crespo2, Lorna Alexander2, José Peña3, Felipe García2, Francisco Borrego  Front Immunol. 2017 Jul 21;8:836. doi: 10.3389/fimmu.2017 
  • Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B. 
    Miriam Rosás-Umbert1,2*, Beatriz Mothe1,3,4*, Marc Noguera-Julian1,4, Rocío Bellido1, MC Puertas1, Jorge Carrillo1, C. Rodriguez1, Núria Perez3, Patricia Cobarsí3, Mariano Esteban5, Jose Luis Jímenez6, Felipe García7, Julià Blanco1,4, Javier M-Picado1,3,8, Roger Paredes1,2,3,4, Christian Brander.  PLoS One 2017; 12(9):e0184929. 
  • Tenofovir/Emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a Single Tablet Regimen for HIV postexposure prophylaxis. 
    Alexy Inciarte12, Lorna Leal1,2, Eva González1, Agathe León1,2, Constanza Lucero1, Josep Mallolas1, Berta Torres1 Montserrat Laguno1, Jhon Rojas 1, María Martínez-Rebollar1, Ana González-Cordón1, Anna Cruceta1, Joan Albert Arnaiz1, Josep M Gatell1,2 and Felipe García1,2 for the STRIBPEP study group.  Journal of Antimicrobial Chemotherapy 2017; 72(10):2857-2861. 
  • Impact of Long-term Antiretroviral Therapy Interruption and Resumption on Viral Reservoir in HIV-1 Infected Patients 
    Marta montserrat1*, Montserrat Plana1*, Alberto C. Guardo1, Cristina Andrés1, Nuria Climent1, Teresa Gallart1, Lorna Leal1, Josep M Gatell1, Sonsoles Sánchez-Palomino1*, Felipe García1*.  AIDS. 2017 Aug 24;31(13):1895-1897 
  • New Challenges in Therapeutic Vaccines Against HIV Infection. 
    Lorna Leal1, Constanza Lucero1, Josep M Gatell1, Teresa Gallart2, Montserrat Plana2, Felipe García1.  Expert Rev Vaccines. 2017; 16(6):587-600. 
  • Executive summary: Pre-exposure prophylaxis for prevention of HIV infection in adults in Spain: July 2016. 
    Moreno S, Antela A, García F, Del Amo J, Boix V, Coll P, Fortuny C, Sirvent JL, Gutiérrez F, Iribarren JA, Llibre JM, Quirós JC, Losa JE, Lozano A, Meulbroek M, Olalla J, Pujol F, Pulido F, Crespo Casal M, García JG, Aldeguer JL, Molina JA, Podzamczer Palter D, Román AR; Grupo Redactor de GESIDA/SEIMC. Grupo de Estudio de Sida de la SEIMC (GeSIDA).  Enferm Infecc Microbiol Clin. 2017; 35(6):377-383. 
  • Utility of Systematic Isolation of immune cell subsets from HIV-infected individuals for miRNA profiling. 
    Manel E Bargalló, Alberto C. Guardo, M.J. Maleno, L. Miralles, L. Egaña-Gorroño, T. Escribà, Felipe Garcia, JOSE MARIA GATELL, M. Arnedo, Montserrat Plana Prades.  JJ Immunol Methods. 2017 ;442:12-19. 
  • Preclinical evaluation of HIV-Specific immune responses upon Stimulation with the mRNA vaccine candidate HTI+ TriMix in mouse and human models. 
    Alberto C. Guardo (1)*; Patrick Tjok Joe(2)*; L. Miralles(1) ;M.E. Bargalló (1); M.J. Maleno (1) ; B. Mothe, A. Krasniqi(2), C. Heirman(2); F. García (3); J..M. Gatell (3); Kris Thielemans(2); Christian Brander, Joeri L. Aerts (2)*; & Montserrat Plana (1)* # on behalf of the iHIVARNA consortium.  AIDS 2017; 31(3):321-332. 

Related Assets

Network